报价延迟最少15分钟:2025/07/17 11:19 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.15 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.37/0.60
|
|
企业价值
331.54M
|
| 资产负债 |
|
每股账面净值
2.79
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
22.27M
|
|
每股收益
0.21
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/07/17 11:19 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat. |
